版本:
中国

BRIEF-BiondVax Phase 2b European Trial: Last Patient Out

Sept 21 BiondVax Pharmaceuticals Ltd

* Last participant in a European phase 2b clinical trial of M-001, its universal flu vaccine candidate, has completed final visit

* Top line results expected in coming months Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐